Investment Rating - The report maintains an "Overweight" rating for the non-bank financial sector [1] Core Insights - The non-bank financial sector is expected to see significant valuation improvement, with catalysts anticipated from upcoming quarterly reports [1] - The insurance sector is experiencing rapid asset growth and an increase in equity allocation, while the securities sector is benefiting from rising trading volumes and supportive regulatory developments [3][21] - The multi-financial sector is transitioning into a stable growth phase, with trust and futures industries showing varied performance and potential for innovation [33][37] Summary by Sections Non-Bank Financial Sector Performance - In the recent five trading days (March 9-13, 2026), all sub-sectors of non-bank financials underperformed the CSI 300 index, with declines of 1.72% in securities, 2.05% in insurance, and 2.79% in multi-financials, while the overall non-bank financial sector fell by 1.82% [8][9] Securities Sector - Trading volume has increased month-on-month, with March's average daily trading volume reaching 29,726 billion yuan, a year-on-year increase of 73.84% and a month-on-month increase of 10.55% [14] - The margin financing balance as of March 12, 2026, was 26,647 billion yuan, up 37.75% year-on-year and 4.88% since the beginning of the year [14] - The average price-to-book (PB) ratio for the securities sector is projected at 1.2x for 2026, indicating potential for growth in leading firms like CITIC Securities and Tonghuashun [21] Insurance Sector - By the end of 2025, total assets of insurance companies reached 41.3 trillion yuan, a 15.1% increase from the beginning of the year [23] - The insurance sector's premium income for 2025 was 6.1 trillion yuan, reflecting a year-on-year growth of 7.4% [24] - The average solvency ratio for insurance companies was 181.1% at the end of 2025, indicating strong financial health [24] Multi-Financial Sector - The trust industry saw its asset scale reach 32.43 trillion yuan by mid-2025, a year-on-year growth of 20.11% [33] - The futures market recorded a trading volume of 5.03 billion contracts in February 2026, with a transaction value of 55.59 trillion yuan, showing a year-on-year increase in transaction value of 7.82% [37] - The report suggests that innovation in risk management will be a key focus for the futures industry moving forward [41] Industry Ranking and Recommendations - The report ranks the insurance sector highest, followed by securities and other multi-financials, recommending companies such as China Ping An, China Taiping, and CITIC Securities for investment [48]

Investment Rating - The report maintains a "Buy" rating for the industry, focusing on companies involved in brain-computer interfaces and innovative pharmaceuticals [1]. Core Insights - The report highlights significant advancements in the brain-computer interface sector, particularly the approval of the world's first invasive brain-computer interface by BoRuiKang, marking a pivotal moment for commercialization in this field [18][24]. - The report emphasizes a favorable outlook for innovative drugs, particularly in the small nucleic acid segment, and suggests a diversified investment strategy across various sub-sectors within the pharmaceutical industry [3][11]. Summary by Sections Industry Performance - The A-share pharmaceutical index has shown a slight decline of -0.22% this week and -0.13% year-to-date, underperforming the CSI 300 index by -0.41% and -0.97% respectively [11]. - The report notes that the medical device sector has seen a positive performance, with raw materials and medical devices increasing by 1.32% and 0.60% respectively [11]. Brain-Computer Interface Developments - BoRuiKang's invasive brain-computer interface, NEO, has received approval from the National Medical Products Administration, representing a breakthrough in the commercialization of brain-computer interfaces [18][20]. - The product is designed for patients with cervical spinal cord injuries, utilizing a minimally invasive implantation technique that reduces risks associated with traditional methods [20][24]. Investment Recommendations - The report ranks sub-sectors in the following order of attractiveness: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [3][11]. - Specific companies to watch include: - PD1 PLUS: Sanofi Biopharma, Kangfang Biopharma, and others [14]. - ADC: YingEn Biopharma, Kelun Biotech, and others [14]. - Small nucleic acids: Frontier Biopharma, Fuyuan Biopharma, and others [14]. - CXO and research services: WuXi AppTec, Haoyuan Biopharma, and others [14]. - Medical devices: United Imaging Healthcare, Yuyue Medical, and others [14]. Regulatory and Market Insights - The report discusses the supportive regulatory environment for brain-computer interfaces, with policies aimed at facilitating research and commercialization [24]. - It also highlights the importance of technological breakthroughs in driving the industry forward, with BoRuiKang setting a benchmark for future product approvals [24].

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, focusing on brain-machine interface technologies and companies like Microinvasive Brain Science, Xiangyu Medical, and Aipeng Medical [1]. Core Insights - The report highlights significant advancements in the brain-machine interface sector, particularly the approval of the first product, which marks a pivotal moment for the industry. This approval is expected to facilitate further commercialization and development within the sector [18][24]. - The report ranks sub-industries in the following order of attractiveness: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies. It emphasizes high elasticity in innovative drugs, especially in small nucleic acid therapies, and high dividend yields in traditional Chinese medicine and pharmacies [3][11]. Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a slight decline of -0.22% this week and -0.13% year-to-date, underperforming the CSI 300 index by -0.41% and -0.97% respectively. The Hang Seng Biotechnology Index has also decreased by -4.00% this week [11]. - Notable stock performances include Yingke Medical (+35.18%), Zhonghong Medical (+25.26%), and *ST Jingfeng (+15.64%) for gains, while Yifang Biological (-11.59%) and Huakang Clean (-10.79%) faced significant losses [11]. R&D Progress and Company Dynamics - The report details the approval of several innovative drugs, including HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enoglutide, which has received approval in China [2][3]. - Companies to watch include: - From the PD1 PLUS perspective: Sanofi Biopharma, Kangfang Biopharma, and others - From the ADC perspective: Ying'en Biopharma and others - From the small nucleic acid perspective: Frontier Biopharma and others - From the CXO and upstream research services perspective: WuXi AppTec and others [3][14]. Brain-Machine Interface Developments - The report emphasizes the approval of the NEO brain-machine interface by the National Medical Products Administration, which is the first of its kind globally. This product is designed for patients with cervical spinal cord injuries and offers a minimally invasive solution with high signal quality and low tissue damage [18][20]. - The approval is seen as a breakthrough that sets a standard for future products in the brain-machine interface space, supported by government policies and funding initiatives aimed at fostering industry growth [24][25].

固收周报 20260315 "新"叙事下十只攻守兼备转债标的筛推 2026 年 03 月 15 日 证券分析师 李勇 执业证书：S0600519040001 010-66573671 liyong@dwzq.com.cn 证券分析师 陈伯铭 执业证书：S0600523020002 chenbm@dwzq.com.cn 证券研究报告·固定收益·固收周报 相关研究 《绿色债券周度数据跟踪（20260309- 20260313）》 2026-03-14 《二级资本债周度数据跟踪 （20260309-20260313）》 2026-03-14 东吴证券研究所 1 / 14 请务必阅读正文之后的免责声明部分 [Table_Tag] [Table_Summary] ◼ 上周（0309－0313）海外方面地缘波动进一步演化，主要大类资 产波动率显著放大，除原油外，避险、风险资产普遍承压，现金 占优隐含"滞胀"隐忧加剧。核心判断在于滞胀预期后市的演化 路径，思考框架上我们认为应该回归到 24－25 年原油熊市为何 发生，包括供给端页岩油革命带来北美产量激增、OPEC+为保 份额而被动放弃减产协议，以及需求端全球能源转型、全球 ...

Market Performance - As of March 13, 2026, the North Exchange A-share index has 298 constituent stocks with an average market capitalization of 3.006 billion yuan[26] - The North Exchange 50 index decreased by 2.15% compared to the previous week's closing price[6] - The average daily trading volume for North Exchange A-shares was approximately 19.729 billion yuan, a decrease of 16.71% from the previous week[6] Industry Insights - The International Energy Agency reported that the global oil market is facing the most severe supply disruptions in history due to ongoing tensions in the Middle East, with a projected drop in global crude oil supply by about 8 million barrels per day in March[18] - Domestic gasoline and diesel prices increased by 695 yuan and 670 yuan per ton, respectively, effective March 9, 2026, due to rising international oil prices[11] Investment Recommendations - The price-to-earnings (PE) ratios for various markets as of March 13, 2026, are as follows: North Exchange A-shares at 64.52, ChiNext at 73.60, Shanghai Main Board at 14.25, Shenzhen Main Board at 44.38, and Sci-Tech Innovation Board at 228.45[39] - Investors are advised to focus on stocks with earnings exceeding expectations and those in innovative growth sectors that align with industrial policies, as well as undervalued stocks[39] Risks - Policy risks may affect market stability, particularly if key institutional advancements do not meet expectations[40] - Liquidity risks persist, as the North Exchange's overall liquidity remains lower than that of the main boards, which could lead to insufficient liquidity during market sentiment shifts[40] - External environmental volatility, including U.S. interest rate policies and geopolitical risks, may disrupt market sentiment and capital flows[40]

Investment Rating - The report maintains a "Buy" rating for the mechanical equipment industry, with a focus on specific companies such as SANY Heavy Industry and XCMG [1][28]. Core Views - The report highlights the acceleration of PCB equipment expansion driven by increased capital expenditure from PCB manufacturers, predicting significant sales growth for PCB equipment companies in 2026-2027 [1]. - The gas turbine industry is expected to benefit from the growing demand for natural gas power generation, particularly in North America, as companies commit to self-sufficient power solutions [2][46]. - The engineering machinery sector is entering an export cycle, with a notable increase in overseas demand, particularly from Europe and Africa, which is expected to drive performance and valuation improvements in 2026 [3][28]. Summary by Sections PCB Equipment - PCB manufacturers are increasing capital expenditures, with notable investments from companies like Huadian and Pengding Holdings, indicating a robust growth outlook for PCB equipment sales [1]. - The report recommends specific companies in the PCB equipment and consumables segment, including Dazhu CNC and Keg Precision [1]. Gas Turbines - The report emphasizes the investment opportunities in the domestic gas turbine supply chain, driven by the supply-demand imbalance and the challenges faced by major international manufacturers [2]. - Recommended companies in the gas turbine sector include Jereh and Dongfang Electric [2]. Engineering Machinery - The report notes a significant increase in excavator exports, with a 37.2% year-on-year growth in February 2026, indicating a strong recovery in the export market [3]. - Key recommendations for the engineering machinery sector include SANY Heavy Industry, XCMG, and LiuGong, as they are expected to benefit from the ongoing export cycle [3][28]. Semiconductor Equipment - The semiconductor equipment market is experiencing a surge in demand driven by AI and advanced logic production, with significant capital expenditures expected from leading companies [20][21]. - The report recommends companies like Northern Huachuang and Zhongwei Technology for their potential in the semiconductor equipment sector [20]. General Investment Opportunities - The report identifies three major opportunities for the mechanical equipment industry: the acceleration of Chinese investments abroad, the recovery of European and American markets, and the technological advancements in equipment manufacturing [40][41]. - Specific companies recommended for investment include SANY Heavy Industry, XCMG, and Jereh, which are well-positioned to capitalize on these trends [40].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has achieved a breakthrough in RDMA high-speed networking with the launch of its first fully self-developed 400G lossless high-speed network product, scaleFabric, which fills a gap in the domestic data center high-speed network field [2] - The scaleFabric400 series network products are fully self-developed, covering everything from the underlying 112G SerDes IP and hardware devices to upper-layer management software, and they match or exceed some specifications of NVIDIA's NDR [2] - The company has successfully developed a domestic InfiniBand-like RDMA high-speed network, addressing the core demands of high bandwidth, low latency, and lossless transmission for large-scale cluster networking [3] - The scaleFabric product is compatible with existing InfiniBand application ecosystems, allowing seamless migration of applications without code modification, and supports large-scale expansion capabilities [3] - The product has been deployed in a national supercomputing internet core node, validating its stability and performance in large-scale cluster environments [10] Financial Projections - The company forecasts total revenue to grow from 6,012 million RMB in 2023 to 28,840 million RMB by 2027, with a compound annual growth rate (CAGR) of approximately 40.23% [1] - The net profit attributable to the parent company is projected to increase from 1,263 million RMB in 2023 to 6,506 million RMB in 2027, reflecting a CAGR of approximately 57.84% [1] - The earnings per share (EPS) is expected to rise from 0.54 RMB in 2023 to 2.80 RMB in 2027 [1] - The price-to-earnings (P/E) ratio is projected to decrease from 433.78 in 2023 to 84.22 by 2027, indicating an improving valuation as earnings grow [1]

1. Report Industry Investment Rating - No information provided in the given content 2. Core View of the Report - The tense situation in the Middle East has caused high - level fluctuations in oil prices, which in turn drives up the overall prices of chemical products [1] 3. Summary by Relevant Catalogs 3.1 Basic Chemical Weekly Data Briefing 3.1.1 Related Company Performance Tracking - The Basic Chemical Index had a 0.6% increase in the past week, 5.4% in the past month, 27.1% in the past three months, 49.5% in the past year, and 19.2% since the beginning of 2026 [8] - Among related companies, the stock prices of Baofeng Energy had significant increases, with a 21.2% increase in the past week, 44.6% in the past month, 95.6% in the past three months, 112.9% in the past year, and 76.8% since the beginning of 2026; while Wanhua Chemical's stock price decreased by 9.1% in the past week [8] 3.1.2 Related Company Profit Tracking - The total market value, net profit attributable to the parent company, PE, and PB of companies such as Wanhua Chemical, Baofeng Energy, Satellite Chemical, Hualu Hengsheng, New Hope Liuhe, and Adisseo were presented, with some data being the forecasts of Soochow Securities Research Institute [8] 3.1.3 Industry Chain Data - **Polyurethane Industry Chain**: The weekly average prices of pure MDI, polymer MDI, and TDI were 20457 yuan/ton, 16500 yuan/ton, and 17996 yuan/ton respectively, with month - on - month increases of 2114 yuan/ton, 1893 yuan/ton, and 2283 yuan/ton respectively; the corresponding gross profits were 5175 yuan/ton, 2218 yuan/ton, and 4510 yuan/ton, with month - on - month changes of +576 yuan/ton, +355 yuan/ton, and - 33 yuan/ton respectively [2][8] - **Oil - Gas - Olefin Industry Chain**: The average prices of ethane, propane, steam coal, and naphtha were 1250 yuan/ton, 6376 yuan/ton, 520 yuan/ton, and 6435 yuan/ton respectively, with month - on - month increases of 44 yuan/ton, 887 yuan/ton, 0 yuan/ton, and 1211 yuan/ton respectively. The average price of polyethylene was 8865 yuan/ton, with a month - on - month increase of 1215 yuan/ton; the theoretical profits of ethane cracking, CTO, and naphtha cracking to produce polyethylene were 1997 yuan/ton, 2556 yuan/ton, and - 1426 yuan/ton respectively, with month - on - month changes of +753 yuan/ton, +793 yuan/ton, and - 383 yuan/ton respectively. The average price of polypropylene was 8910 yuan/ton, with a month - on - month increase of 1640 yuan/ton; the theoretical profits of PDH, CTO, and naphtha cracking to produce polypropylene were - 781 yuan/ton, 2798 yuan/ton, and - 1028 yuan/ton respectively, with month - on - month changes of +306 yuan/ton, +1088 yuan/ton, and - 89 yuan/ton respectively [2][8] - **Coal - Chemical Industry Chain**: The average prices of synthetic ammonia, urea, DMF, and acetic acid were 2087 yuan/ton, 1839 yuan/ton, 5114 yuan/ton, and 2767 yuan/ton respectively, with month - on - month increases of 62 yuan/ton, 21 yuan/ton, 1005 yuan/ton, and 191 yuan/ton respectively; the corresponding gross profits were 88 yuan/ton, 154 yuan/ton, 428 yuan/ton, and 383 yuan/ton, with month - on - month increases of 63 yuan/ton, 5 yuan/ton, 169 yuan/ton, and 4 yuan/ton respectively [2][10] - **Animal Nutrition Industry Chain**: The average prices of VA, VE, solid methionine, and liquid methionine were 64.9 yuan/kg, 73.1 yuan/kg, 31.6 yuan/kg, and 19.0 yuan/kg respectively, with month - on - month increases of 4.4 yuan/kg, 9.7 yuan/kg, 10.7 yuan/kg, and 3.3 yuan/kg respectively [2][10] 3.2 Basic Chemical Weekly Report 3.2.1 Basic Chemical Index Trend - No detailed data provided in the given content 3.2.2 Polyurethane Plate - Analyzed the price trends and price - spread situations of pure MDI, polymer MDI, and TDI in China [15][18] 3.2.3 Oil - Gas - Olefin Plate - Studied the price trends of MB ethane, NYMEX natural gas, domestic steam coal, naphtha, crude oil, and propane, as well as the profitability of different processes such as ethane cracking to produce PE, PDH to produce PP, coal - to - PE, coal - to - PP, and naphtha - to - PE/PP [22][23][26][28][29][34][36][37] 3.2.4 Coal - Chemical Plate - Analyzed the price and gross - profit trends of coal - coking products (coking coal, coke), traditional coal - chemical products (synthetic ammonia, methanol, urea, DMF, acetic acid), and new materials (DMC, oxalic acid, octanol, adipic acid, caprolactam, PA6, PA66) [10][39][40][42][46][48][51][53] 3.2.5 Animal Nutrition Plate - Studied the price trends of VE, solid methionine, and liquid methionine [54][56]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has achieved a breakthrough in RDMA high-speed networking with the launch of its first fully self-developed 400G lossless high-speed network product, scaleFabric, which fills a gap in the domestic data center high-speed network field [2] - The scaleFabric400 series network products are fully self-developed, matching and even surpassing some specifications of NVIDIA's NDR, addressing key challenges in large-scale computing clusters [3] - The scaleFabric network supports over 100,000 cards in a single subnet and can achieve deployments of up to one million cards, catering to the exponential growth in AI computing power [3][10] - The company has a complete product matrix in the A-share GPU sector, with its CPU and DCU products positioned to benefit from the accelerating domestic computing infrastructure construction [10] Financial Projections - Total revenue is projected to grow from 6,012 million RMB in 2023 to 28,840 million RMB by 2027, with a compound annual growth rate (CAGR) of approximately 40.23% [1] - Net profit attributable to the parent company is expected to increase from 1,263 million RMB in 2023 to 6,506 million RMB in 2027, reflecting a CAGR of about 57.84% [1] - The earnings per share (EPS) is forecasted to rise from 0.54 RMB in 2023 to 2.80 RMB in 2027 [1] Market Data - The closing price of the company's stock is 235.74 RMB, with a market capitalization of approximately 547,939.46 million RMB [6] - The price-to-earnings (P/E) ratio is projected to decrease from 433.78 in 2023 to 84.22 by 2027, indicating an improving valuation as earnings grow [1][11]

证券研究报告·宏观报告·宏观周报 金融产品周报 20260315 部分热门板块短期承压，中期仍然看好 2026 年 03 月 15 日 [Table_Summary] A 股市场行情概述：（2026.3.9-2026.3.13） 市场行情展望：（2026.3.16-2026.3.20） ◼ 观点：部分热门板块短期承压，中期仍然看好。 基金配置建议： 证券分析师 芦哲 执业证书：S0600524110003 luzhe@dwzq.com.cn 证券分析师 唐遥衎 执业证书：S0600524120016 tangyk@dwzq.com.cn 相关研究 《平滑投放后，3 月份贷款或季节性 冲量——2026 年 2 月金融数据点评 》 2026-03-13 《美国 2 月 CPI："好戏"在后头— —2026 年 2 月美国 CPI 数据点评》 2026-03-12 东吴证券研究所 1 / 19 请务必阅读正文之后的免责声明部分 [Table_Tag] ◼ 权益类 ETF 基金规模变化统计：规模变化排名前三名的权益类 ETF 类 型分别为：策略指数 ETF（74.97 亿元），跨境行业指数 ETF（20.83 亿 元 ...